Literature DB >> 14624913

Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies.

Richard Zigeuner1, Luigi Schips, Katja Lipsky, Marko Auprich, Michael Salfellner, Peter Rehak, Karl Pummer, Gerhart Hubmer.   

Abstract

OBJECTIVES: To evaluate retrospectively the effectiveness of transurethral resection of the prostate (TURP) in diagnosing prostate cancer in patients with obstructive voiding symptoms and a history of negative transrectal prostate biopsy but elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE).
METHODS: In 1189 consecutive patients undergoing TURP or open prostatectomy between 1994 and 2000 for obstructive voiding symptoms, we identified 445 patients (37.4%) with at least one previous set of transrectal prostate biopsies because of an elevated PSA level and/or abnormal DRE findings. The probability to detect prostate cancer by TURP (n = 423; 95%) or open surgery (n = 22; 5%) was investigated overall, as well as related to patient age, PSA level, DRE findings, number of previous biopsies, time from biopsy to surgery, and weight of resected tissue.
RESULTS: The mean number of preoperative negative biopsies per patient was 1.6 (range 1 to 8). The mean patient age was 69 years (range 48 to 89). The median PSA level and resection weight was 8.64 ng/mL and 32 g, respectively. Ninety-seven patients (21.8%) had abnormal DRE findings. Overall, prostate cancer was detected in 35 patients (7.9%). The cancer incidence was 5.5% (19 of 348) in patients with a normal DRE compared with 16.5% (16 of 97) in patients with an abnormal DRE (P <0.001; Fisher's exact test). The cancer rate was also related to age; other subgroups showed no statistically significant differences regarding cancer incidence.
CONCLUSIONS: In patients with previously negative biopsies, the diagnostic yield of TURP is low. Therefore, TURP for diagnostic purposes only cannot be recommended. However, in patients with an abnormal DRE and obstructive symptoms, surgery should be preferred over alternative treatment options.

Entities:  

Mesh:

Year:  2003        PMID: 14624913     DOI: 10.1016/s0090-4295(03)00663-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Prostate cancer detected after Holmium laser enucleation of prostate (HoLEP): significance of transrectal ultrasonography.

Authors:  Myong Kim; Sang Hoon Song; Ja Hyeon Ku; Seung-June Oh; Jae-Seung Paick
Journal:  Int Urol Nephrol       Date:  2014-07-01       Impact factor: 2.370

2.  Informative value of histological assessment of tissue acquired during aquablation of the prostate.

Authors:  Gautier Müllhaupt; Annette Enzler-Tschudy; Katarina Horg; Lukas Bubendorf; Manolis Pratsinis; Hans-Peter Schmid; Dominik Abt
Journal:  World J Urol       Date:  2020-09-09       Impact factor: 4.226

3.  Is sampling transitional zone in patients who had prior negative prostate biopsy necessary?

Authors:  Bayram Dogan; Ege Can Serefoglu; Ali Fuat Atmaca; Abdullah Erdem Canda; Ziya Akbulut; M Derya Balbay
Journal:  Int Urol Nephrol       Date:  2012-03-15       Impact factor: 2.370

4.  Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link?

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Philip Van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2007-06-30       Impact factor: 2.370

5.  Role of Hiraoka's transurethral detachment of the prostate combined with biopsy of the peripheral zone during the same session in patients with repeated negative biopsies in the diagnosis of prostate cancer.

Authors:  Chun-Yu Pan; Bin Wu; Zi-Chuan Yao; Xian-Qing Zhu; Yun-Zhong Jiang; Song Bai
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

6.  Diagnostic role of prostate resection in the elderly patients who experience significant co-morbidity with a high clinical suspicion of prostate cancer.

Authors:  Ho Won Kang; Jin Bak Yang; Whi-An Kwon; Young-Suk Lee; Won Tae Kim; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Isaac Yi Kim; Wun-Jae Kim
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

7.  Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia.

Authors:  Rasa Ruseckaite; Fanny Sampurno; Jeremy Millar; Mark Frydenberg; Sue Evans
Journal:  BMC Urol       Date:  2016-09-02       Impact factor: 2.264

8.  Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.

Authors:  Mohammad Hassan Heidari; Abolfazl Movafagh; Mohammad-Amin Abdollahifar; Shabnam Abdi; Mohamadreza Mashhoudi Barez; Hadi Azimi; Afshin Moradi; Amin Bagheri; Matineh Heidari; Jafar Hessam Mohseni; Maryam Tadayon; Hoda Mirsafian; Mahdi Ghatrehsamani
Journal:  Anat Cell Biol       Date:  2017-03-29

Review 9.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

10.  Should all specimens taken during surgical treatment of patients with benign prostatic hyperplasia be assessed by a pathologist?

Authors:  Michał Andrzej Skrzypczyk; Jakub Dobruch; Lukasz Nyk; Przemysław Szostek; Stanisław Szempliński; Andrzej Borówka
Journal:  Cent European J Urol       Date:  2014-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.